Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops promise quick redness relief

NCT ID NCT06444529

Symptom relief Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special eye drop (apraclonidine) can safely reduce eye redness caused by minor irritations. 159 adults who often use redness-relief drops took part. Researchers measured redness before and after using the drops, checking at 15 minutes and 10 hours later. The goal was to see if the drops work better than a placebo (fake drops).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

159 people

The number who actually took part.

Started

Aug 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Capable of giving signed informed consent; * Willing and able to follow all instructions and attend all study visits; * Able to self-administer eye drops- in the opinion of the investigator; * History of redness relief drop use within the last 6 months, or a desire to use over-the-counter (OTC) eye drops for redness relief; * Females capable of becoming pregnant: Agree to urine pregnancy tests and the use of medically acceptable forms of birth control throughout the study; * Ocular health within normal limits, including best-corrected visual acuity (BCVA) of 20/40 or better in each eye as measured using a Snellen chart; * Ocular redness at baseline as specified in the protocol; * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivities to the use of any of the investigational drug(s) or their components, or any other medication required by the protocol; * Ocular surgical interventions within 6 months prior to Visit 1 or during the study; * Ocular conditions that, in the opinion of the investigator, could affect the subject's safety or study parameters (i.e., could affect ocular redness, intraocular pressure, or eyelid position); * Disallowed medications or devices as specified in the protocol; * Planned surgery (ocular or systemic) during the study period or within 30 days after the study period; * Other protocol-defined exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular redness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ocular hyperemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular redness

Contacts and locations

Locations

  • Emerson Clinical Research Institute, Inc.

    Falls Church, Virginia, 22046, United States

  • Global Research Management

    Glendale, California, 91204, United States

  • Oculus Research, Inc.

    Garner, North Carolina, 27529, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Scott & Christie and Associates, PC

    Cranberry Township, Pennsylvania, 16066, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.